ABL1 is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 24 clinical trials for primary myelofibrosis, of which 23 are open and 1 is closed. Of the trials that contain AFF1 status and primary myelofibrosis as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BCR is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains BCR status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CALR is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains CALR status and primary myelofibrosis as inclusion criteria, 1 is phase 1 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains DEK status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ELL is an inclusion eligibility criterion in 24 clinical trials for primary myelofibrosis, of which 23 are open and 1 is closed. Of the trials that contain ELL status and primary myelofibrosis as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and primary myelofibrosis as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and primary myelofibrosis as inclusion criteria, 1 is phase 1 (1 open) [3].

JAK2 is an inclusion eligibility criterion in 2 clinical trials for primary myelofibrosis, of which 1 is open and 1 is closed. Of the trials that contain JAK2 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 25 clinical trials for primary myelofibrosis, of which 23 are open and 2 are closed. Of the trials that contain KMT2A status and primary myelofibrosis as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [3].

MECOM is an inclusion eligibility criterion in 25 clinical trials for primary myelofibrosis, of which 23 are open and 2 are closed. Of the trials that contain MECOM status and primary myelofibrosis as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 24 clinical trials for primary myelofibrosis, of which 23 are open and 1 is closed. Of the trials that contain MLLT1 status and primary myelofibrosis as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [3].

MLLT10 is an inclusion eligibility criterion in 24 clinical trials for primary myelofibrosis, of which 23 are open and 1 is closed. Of the trials that contain MLLT10 status and primary myelofibrosis as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [3].

MLLT3 is an inclusion eligibility criterion in 24 clinical trials for primary myelofibrosis, of which 23 are open and 1 is closed. Of the trials that contain MLLT3 status and primary myelofibrosis as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [3].

MLLT4 is an inclusion eligibility criterion in 24 clinical trials for primary myelofibrosis, of which 23 are open and 1 is closed. Of the trials that contain MLLT4 status and primary myelofibrosis as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 24 clinical trials for primary myelofibrosis, of which 23 are open and 1 is closed. Of the trials that contain NRIP3 status and primary myelofibrosis as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains NUP214 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 25 clinical trials for primary myelofibrosis, of which 23 are open and 2 are closed. Of the trials that contain RPN1 status and primary myelofibrosis as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [3].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].